- Home
- REFR vs RLAY Comparison
REFR vs RLAY Comparison
Compare REFR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- RLAY
- Stock Information
- Founded
- REFR 1965
- RLAY 2015
- Country
- REFR United States
- RLAY United States
- Employees
- REFR N/A
- RLAY N/A
- Industry
- REFR Multi-Sector Companies
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REFR Miscellaneous
- RLAY Health Care
- Exchange
- REFR Nasdaq
- RLAY Nasdaq
- Market Cap
- REFR N/A
- RLAY 490.3M
- IPO Year
- REFR N/A
- RLAY 2020
- Fundamental
- Price
- REFR $1.83
- RLAY $3.00
- Analyst Decision
- REFR
- RLAY Strong Buy
- Analyst Count
- REFR 0
- RLAY 11
- Target Price
- REFR N/A
- RLAY $18.40
- AVG Volume (30 Days)
- REFR 52.9K
- RLAY 2.2M
- Earning Date
- REFR 05-08-2025
- RLAY 05-05-2025
- Dividend Yield
- REFR N/A
- RLAY N/A
- EPS Growth
- REFR N/A
- RLAY N/A
- EPS
- REFR N/A
- RLAY N/A
- Revenue
- REFR $1,581,929.00
- RLAY $7,679,000.00
- Revenue This Year
- REFR N/A
- RLAY N/A
- Revenue Next Year
- REFR N/A
- RLAY $169.23
- P/E Ratio
- REFR N/A
- RLAY N/A
- Revenue Growth
- REFR 62.28
- RLAY N/A
- 52 Week Low
- REFR $0.93
- RLAY $1.78
- 52 Week High
- REFR $2.42
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- REFR 73.06
- RLAY 51.78
- Support Level
- REFR $1.65
- RLAY $2.75
- Resistance Level
- REFR $2.00
- RLAY $3.10
- Average True Range (ATR)
- REFR 0.11
- RLAY 0.20
- MACD
- REFR 0.02
- RLAY 0.01
- Stochastic Oscillator
- REFR 61.11
- RLAY 54.10
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).